| (P291) |
Determination of a reference value for asymmetrical dimethylarginine in a cohort of 500 healthy subjects. |
|
F. Schulze, R. Maas, R. Freese, E. Schwedhelm, E. Silberhorn, R.H. Böger (Hamburg, DE) |
| (P292) |
Asymmetric dimethylarginine (ADMA): predictive power for acute coronary events in apparently healthy men depends on smoking status. |
|
R. Maas, F. Schulze, J. Baumert, H. Löwel, R. Böger, W. König (Hamburg, Neuherberg and Ulm, DE) |
| (P293) |
Pathophysiological concentrations of ADMA alter human coronary artery endothelial cell gene expression: an insight into the pathophysiological significance of raised plasma ADMA levels. |
|
C. Smith, S. Anthony, M. Malaki, M. Hubank, J. Leiper, P. Vallance (London, GB) |
| (P294) |
Plasma concentrations of asymmetric dimethylarginine are associated with titers of anti-dsDNA antibodies, cardiovascular events and disease activity in patients with systemic lupus erythematosus. |
|
T. Teerlink, I. Bultink, H. Heijst, B. Dijkmans, A. Voskuyl (Amsterdam, NL) |
| (P295) |
Regulatory effects of NOS inhibitors on the activity of Rho GTPases and endothelial function in pulmonary macro and microvascular endothelial cells in vitro. |
|
L. Yen Fen Tsang, P. Vallance, J. Leiper, B. Wojciak-Stothard (London, GB) |
| (P296) |
Effect of experimental myocardial infarction on the expression of dimethylarginine dimethylaminohydrolase isoforms (DDAH I and II) and ADMA concentrations in the heart. |
|
G. Gray, M. Patrizio, M. Malaki, L. Sherry, A. Miller, A. Wallace, J. Leiper, P. Vallance (Edinburgh and London, GB) |
| (P297) |
Potential therapeutic benefit of novel DDAH inhibitors for the treatment of endotoxemia. |
|
M. Nandi, S. Rossiter, B. Torondel, M. Malaki, C. Smith, R. Stidwill, J. Leiper, P. Vallance (London, GB) |
| (P298) |
Prognostic value of brachial artery endothelial function and wall thickness. |
|
A. Suessenbacher, M. Frick, H.F. Alber, W. Dichtl, O. Pachinger, F. Weidinger (Innsbruck, AT) |
| (P299) |
Improvement in rather than single assessment of brachial artery endothelial function predicts cardiovascular events in coronary artery disease patients. |
|
A. Suessenbacher, M. Frick, H. Alber, O. Pachinger, F. Weidinger (Innsbruck, AT) |
| (P300) |
Molecular basis for vascular protection by atorvastatin in L-name induced accelerated hypertension. |
|
M. Dupuis, S. Nadaud, I. Brocheriou, S. Raoux, M. Haloui, L. Louedec, F. Capron, J-B. Michel, F. Soubrier (Paris, FR) |
| (P301) |
Distribution and vasodilatory function of nitric oxide and superoxide after myocardial infarction. |
|
A. Berges, L. Van Nassauw, J-P. Timmermans, Chr. Vrints (Antwerp, BE) |
| (P302) |
Endothelial nitric oxide synthase is essential for vasodilation during blood flow recovery , but not for collateral artery growth. |
|
B. Mees, S. Wagner, E. Ninci, S. Tribulova, S. Martin, R. van Haperen, S. Kostin, M. Heil, R. de Crom, W. Schaper (Rotterdam, NL; Bad Nauheim, DE) |
| (P303) |
Condition of nitric oxide system, free radical lipid peroxidation processes and a fat acids spectrum of blood of patients with primary right ventricular heart failure owing to pulmonary hypertension. |
|
E.N. Amosova, E.M. Zadorin, L.F. Konopleva (Kiev, UA) |